Author: Bill Snyder
Jan. 24, 2019—Angelika Amon, PhD, recipient of the 2018 Vanderbilt Prize in Biomedical Science, will deliver her Vanderbilt Prize lecture at 4 p.m. Thursday, Jan. 31, in 208 Light Hall.
Jan. 24, 2019—The year is starting off with a bang for Craig Lindsley, PhD, director of medicinal chemistry in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD).
Jan. 24, 2019—Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus.
Jan. 10, 2019—Craig Lindsley, PhD, a leader of Vanderbilt University School of Medicine’s groundbreaking drug discovery program, is being honored by the American Society for Pharmacology and Experimental Therapeutics (ASPET) for his transformative approaches to identifying potential new drugs.
Dec. 20, 2018—Craig Lindsley, PhD, co-director of the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD), has been named a fellow of the National Academy of Inventors (NAI).
Dec. 6, 2018—Pulmonary-renal syndrome (PRS) refers to a group of rare but potentially fatal conditions that nearly always are caused by a misguided attack by the body’s immune system on the lungs and kidneys. Coughing up blood and blood in the urine are telltale signs.
Dec. 6, 2018—Researchers at Vanderbilt University Medical Center and colleagues have isolated a human monoclonal antibody that can “neutralize” the West Nile virus and potentially prevent a leading cause of viral encephalitis (brain inflammation) in the United States.